Johnson & Johnson, a holding company, which engages in the health care field, completed the acquisition of TARIS Biomedical, a pharmaceutical company, from Polaris Partners, Flagship Pioneering, Yonghua Capital and RA Capital. Financial terms were not disclosed. "The TARIS technology and scientific team create an unparalleled convergence opportunity with real potential to deliver differentiated, targeted therapeutics for the treatment of patients with localized bladder cancer," Mathai Mammen, Janssen Global Head.